Comparative Pharmacology
Head-to-head clinical analysis: SULLA versus UROPLUS DS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULLA versus UROPLUS DS.
SULLA vs UROPLUS DS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
SULLA (sulfamethoxazole/trimethoprim) inhibits bacterial dihydropteroate synthase and dihydrofolate reductase, sequentially blocking folate synthesis and thereby nucleic acid production.
UROPLUS DS is a combination of sulfamethoxazole, a sulfonamide, and trimethoprim, a dihydrofolate reductase inhibitor. Sulfamethoxazole inhibits bacterial synthesis of dihydrofolic acid by competing with para-aminobenzoic acid (PABA). Trimethoprim inhibits dihydrofolate reductase, blocking the reduction of dihydrofolic acid to tetrahydrofolic acid. This sequential blockade disrupts folic acid synthesis, leading to bacterial growth inhibition.
100 mg orally once daily, increased to 200 mg daily if needed.
UROPLUS DS (methenamine mandelate 1 g + sodium acid phosphate 500 mg) oral: 1 tablet twice daily.
None Documented
None Documented
6-12 hours; prolonged in renal impairment (up to 30 hours)
Terminal elimination half-life is 11-13 hours in adults with normal renal function; prolonged to 16-20 hours in moderate renal impairment (CrCl 30-50 mL/min) and up to 25 hours in severe impairment (CrCl <30 mL/min).
Renal: 70-90% unchanged; biliary/fecal: 5-10%
Renal excretion of unchanged drug accounts for approximately 40-50% of elimination; hepatic metabolism (primarily via CYP3A4) and subsequent biliary/fecal excretion constitute the remainder with about 20-30% recovered in feces as metabolites.
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic